Healthcare Resource Utilization 6 Weeks Post-Diagnosis Among Individuals With Major Depressive Disorder in the United States

Abstract: Background: Although major depressive disorder (MDD) is associated with high economic burden, short-term healthcare resource utilization (HCRU) is poorly understood in patients newly diagnosed with MDD. Objectives: Estimate inpatient and outpatient HCRU among a cohort of patients within 6 weeks following index MDD diagnosis. Methods: IBM MarketScan® claims data (01/01/2016-12/31/2019) were used to identify patients with ≥1 claim with an MDD diagnosis, ≥12 months enrollment before and following first MDD claim (index date), and age ≥18 years. Mean [median] per-patient all-cause and mental health-related HCRU within 6 weeks post-index were reported for the pooled population and separately for commercial, Medicare, and Medicaid populations. Results: The MDD cohort contained 1,034,594 patients (mean age 47 years; 71% female), of which 637,949; 57,607; and 339,038 were Commercial, Medicare, and Medicaid patients, respectively. Combined all-cause inpatient and outpatient visits across six weeks post-index were 0.19 [0] and 4.11 [2], while mental health-related inpatient and outpatient visits were 0.11 [0] and 1.66 [0], respectively. All-cause inpatient and outpatient visits were 0.11 [0] and 2.87 [2] for commercial, 0.50 [0] and 4.14 [3] for Medicare, and 0.27 [0] and 6.45 [3] for Medicaid populations, while mental health-related inpatient and outpatient visits were 0.08 [0] and 1.28 [0] for commercial, 0.18 [0] and 0.96 [0] for Medicare, and 0.16 [0] and 2.51 [1] for Medicaid populations. Conclusions: Understanding real-world all-cause and mental health-related HCRU in the immediate weeks following MDD diagnosis is critical for optimal MDD disease state management and understanding unmet needs when developing new therapies.Short Description: This study evaluates inpatient and outpatient HCRU for an MDD cohort within 6 weeks post-diagnosis. IBM MarketScan® claims data (01/01/2016-12/31/2019) were used to identify adult patients with ≥1 diagnosis claim for MDD, and ≥12 months enrollment before and following the first claim (index date). Understanding real-world all-cause and mental health-related HCRU in the immediate weeks following MDD diagnosis is critical for optimal disease state management and understanding unmet needs when developing new therapies.Name of Sponsoring Organization(s): This study was sponsored by Sage Therapeutics, Inc. and Biogen Inc. Logistical support for this abstract was provided by Boston Strategic Partners, Inc. and Envision Pharma Group and funded by Sage Therapeutics, Inc. and Biogen Inc.